Literature DB >> 27018720

Quantifying homologous and heterologous antibody titre rises after influenza virus infection.

G Freeman1, R A P M Perera1, E Ngan1, V J Fang1, S Cauchemez2, D K M Ip1, J S M Peiris1, B J Cowling1.   

Abstract

Most influenza virus infections are associated with mild disease. One approach to estimate the occurrence of influenza virus infections in individuals is via repeated measurement of humoral antibody titres. We used baseline and convalescent antibody titres measured by haemagglutination inhibition (HI) and viral neutralization (VN) assays against influenza A(H1N1), A(H3N2) and B viruses to investigate the characteristics of antibody rises following virologically confirmed influenza virus infections in participants in a community-based study. Multivariate models were fitted in a Bayesian framework to characterize the distribution of changes in antibody titres following influenza A virus infections. In 122 participants with PCR-confirmed influenza A virus infection, homologous antibody titres rose by geometric means of 1·2- to 10·2-fold after infection with A(H1N1), A(H3N2) and A(H1N1)pdm09. Significant cross-reactions were observed between A(H1N1)pdm09 and seasonal A(H1N1). Antibody titre rises for some subtypes and assays varied by age, receipt of oseltamivir treatment, and recent receipt of influenza vaccination. In conclusion, we provided a quantitative description of the mean and variation in rises in influenza virus antibody titres following influenza virus infection. The multivariate patterns in boosting of antibody titres following influenza virus infection could be taken into account to improve estimates of cumulative incidence of infection in seroepidemiological studies.

Entities:  

Keywords:  Antibody; epidemiology; influenza; serology

Mesh:

Substances:

Year:  2016        PMID: 27018720      PMCID: PMC5530596          DOI: 10.1017/S0950268816000583

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  32 in total

1.  Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong.

Authors:  Gannon C Mak; Perrin W W Choy; W Y Lee; Ann H Wong; K C Ng; Wilina Lim
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

2.  Infection with influenza A H1N1. 1. Production and persistence of antibody.

Authors:  E A Grilli; J R Davies; A J Smith
Journal:  J Hyg (Lond)       Date:  1986-04

3.  Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore.

Authors:  Julian W Tang; Paul A Tambyah; Annelies Wilder-Smith; Kim Yoong Puong; Robert Shaw; Ian G Barr; Kwai Peng Chan
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

4.  Seroconversion to pandemic (H1N1) 2009 virus and cross-reactive immunity to other swine influenza viruses.

Authors:  Ranawaka A P M Perera; Steven Riley; Siu K Ma; Hua-Chen Zhu; Yi Guan; Joseph S M Peiris
Journal:  Emerg Infect Dis       Date:  2011-10       Impact factor: 6.883

5.  Serological response in RT-PCR confirmed H1N1-2009 influenza a by hemagglutination inhibition and virus neutralization assays: an observational study.

Authors:  Mark I Chen; Ian G Barr; Gerald C H Koh; Vernon J Lee; Caroline P S Lee; Robert Shaw; Cui Lin; Jonathan Yap; Alex R Cook; Boon Huan Tan; Jin Phang Loh; Timothy Barkham; Vincent T K Chow; Raymond T P Lin; Yee-Sin Leo
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

6.  The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination.

Authors:  Heath Kelly; Heidi A Peck; Karen L Laurie; Peng Wu; Hiroshi Nishiura; Benjamin J Cowling
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

7.  Comparability of different methods for estimating influenza infection rates over a single epidemic wave.

Authors:  Vernon J Lee; Mark I Chen; Jonathan Yap; Jocelyn Ong; Wei-Yen Lim; Raymond T P Lin; Ian Barr; Jimmy B S Ong; Tze Minn Mak; Lee Gan Goh; Yee Sin Leo; Paul M Kelly; Alex R Cook
Journal:  Am J Epidemiol       Date:  2011-06-30       Impact factor: 4.897

8.  Multivariate analysis of factors affecting the immunogenicity of trivalent inactivated influenza vaccine in school-age children.

Authors:  G Freeman; S Ng; R A P M Perera; V J Fang; D K M Ip; G M Leung; J S M Peiris; B J Cowling
Journal:  Epidemiol Infect       Date:  2014-05-01       Impact factor: 4.434

Review 9.  Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Authors:  Tom Jefferson; Mark Jones; Peter Doshi; Elizabeth A Spencer; Igho Onakpoya; Carl J Heneghan
Journal:  BMJ       Date:  2014-04-09

10.  Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore.

Authors:  Jung Pu Hsu; Xiahong Zhao; Mark I-Cheng Chen; Alex R Cook; Vernon Lee; Wei Yen Lim; Linda Tan; Ian G Barr; Lili Jiang; Chyi Lin Tan; Meng Chee Phoon; Lin Cui; Raymond Lin; Yee Sin Leo; Vincent T Chow
Journal:  BMC Infect Dis       Date:  2014-07-28       Impact factor: 3.090

View more
  9 in total

1.  Incidence of influenza A(H3N2) virus infections in Hong Kong in a longitudinal sero-epidemiological study, 2009-2015.

Authors:  Vivian W I Wei; Jessica Y T Wong; Ranawaka A P M Perera; Kin On Kwok; Vicky J Fang; Ian G Barr; J S Malik Peiris; Steven Riley; Benjamin J Cowling
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

2.  Age-specific differences in the dynamics of protective immunity to influenza.

Authors:  Sylvia Ranjeva; Rahul Subramanian; Vicky J Fang; Gabriel M Leung; Dennis K M Ip; Ranawaka A P M Perera; J S Malik Peiris; Benjamin J Cowling; Sarah Cobey
Journal:  Nat Commun       Date:  2019-04-10       Impact factor: 14.919

Review 3.  Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms.

Authors:  Kashyap R Patel; Jacob T Roberts; Adam W Barb
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

4.  Characterising antibody kinetics from multiple influenza infection and vaccination events in ferrets.

Authors:  James A Hay; Karen Laurie; Michael White; Steven Riley
Journal:  PLoS Comput Biol       Date:  2019-08-19       Impact factor: 4.475

5.  Variation by lineage in serum antibody responses to influenza B virus infections.

Authors:  Yiu Chung Lau; Ranawaka A P M Perera; Vicky J Fang; Long Hei Luk; Daniel K W Chu; Peng Wu; Ian G Barr; J S Malik Peiris; Benjamin J Cowling
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

6.  Etiologies of severe acute respiratory infection (SARI) and misdiagnosis of influenza in Indonesia, 2013-2016.

Authors:  Abu Tholib Aman; Tri Wibawa; Herman Kosasih; Rizka Humardewayanti Asdie; Ida Safitri; Umi Solekhah Intansari; Yuli Mawarti; Pratiwi Sudarmono; Mansyur Arif; Dwiyanti Puspitasari; Bachti Alisjahbana; Ketut Tuti Merati Parwati; Muhammad Hussein Gasem; Dewi Lokida; Nurhayati Lukman; Teguh Sarry Hartono; Yan Mardian; C Jason Liang; Sophia Siddiqui; Muhammad Karyana; Chuen-Yen Lau
Journal:  Influenza Other Respir Viruses       Date:  2020-07-14       Impact factor: 4.380

7.  Epidemiology of repeat influenza infection in Queensland, Australia, 2005-2017.

Authors:  Olivia Price; Frances A Birrell; Edin J Mifsud; Sheena G Sullivan
Journal:  Epidemiol Infect       Date:  2022-07-18       Impact factor: 4.434

8.  An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver.

Authors:  James A Hay; Amanda Minter; Kylie E C Ainslie; Justin Lessler; Bingyi Yang; Derek A T Cummings; Adam J Kucharski; Steven Riley
Journal:  PLoS Comput Biol       Date:  2020-05-04       Impact factor: 4.779

9.  Reconstructing antibody dynamics to estimate the risk of influenza virus infection.

Authors:  Tim K Tsang; Ranawaka A P M Perera; Vicky J Fang; Jessica Y Wong; Eunice Y Shiu; Hau Chi So; Dennis K M Ip; J S Malik Peiris; Gabriel M Leung; Benjamin J Cowling; Simon Cauchemez
Journal:  Nat Commun       Date:  2022-03-23       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.